Lv1
20 积分 2022-09-02 加入
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
2天前
已完结
Emerging targets in gastric and pancreatic cancer: Focus on Claudin 18.2
3个月前
已完结
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
3个月前
已完结
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
4个月前
已完结
Efficacy and safety of recombinant human thrombopoietin for the treatment of chronic primary immune thrombocytopenia in children and adolescents: A multicentre, randomized, double‐blind, placebo‐controlled phase III trial
5个月前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
6个月前
已完结
[Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)]
6个月前
已完结
Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell–engaging bispecific antibody targeting human claudin 6
6个月前
已完结
Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials
7个月前
已完结
Claudin 18.2 as a novel therapeutic target
7个月前
已完结
皖公网安备34019202002308
